Search Results - "Hoeller, C."

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee by Keilholz, U., Ascierto, P.A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Michielin, O.

“…The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5–7 September 2019 in Amsterdam, The Netherlands. The conference…”
Get full text

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee by Michielin, O., van Akkooi, A., Lorigan, P., Ascierto, P.A., Dummer, R., Robert, C., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., Keilholz, U.

“…The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5–7 September 2019 in Amsterdam, The Netherlands. The conference…”
Get full text

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy by Owen, C.N., Shoushtari, A.N., Chauhan, D., Palmieri, D.J., Lee, B., Rohaan, M.W., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hoeller, C., Hersey, P., Dummer, R., Khattak, M.A., Millward, M., Patel, S.P., Haydon, A., Johnson, D.B., Lo, S., Blank, C.U., Sandhu, S., Carlino, M.S., Larkin, J.M.G., Menzies, A.M., Long, G.V.

“…Anti-programmed cell death protein 1 (PD-1) antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25%–30% of…”
Get full text

Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature by Mössner, R., Zimmer, L., Berking, C., Hoeller, C., Loquai, C., Richtig, E., Kähler, K.C., Hassel, J.C., Gutzmer, R., Ugurel, S.

“…Importance BRAF inhibitors have been licensed for the therapy of BRAF‐mutated melanoma. Recently, inflammatory skin lesions clinically resembling erythema…”
Get full text

Talimogene laherparepvec (T‐VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report by Ressler, J., Silmbrod, R., Stepan, A., Tuchmann, F., Cicha, A., Uyanik‐Ünal, K., Hoeller, C.

“…Summary Talimogene laherparepvec (T‐VEC) is a intralesional oncolytic virotherapy, licensed in the European Union for locoregional advanced melanoma of…”
Get full text

Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)—Phase II data covering impact of concomitant haematological malignancies by Lang, R., Welponer, T., Richtig, E., Wolf, I., Hoeller, C., Hafner, C., Nguyen, V. A., Kofler, J., Barta, M., Koelblinger, P., Hitzl, W., Emberger, M., Laimer, M.

“…Background Monoclonal antibodies, such as cemiplimab and pembrolizumab, against the programmed death receptor (PD)‐1 have become the current standard of care…”
Get full text

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries by Kandolf Sekulovic, L., Guo, J., Agarwala, S., Hauschild, A., McArthur, G., Cinat, G., Wainstein, A., Caglevic, C., Lorigan, P., Gogas, H., Alvarez, M., Duncombe, R., Lebbe, C., Peris, K., Rutkowski, P., Stratigos, A., Forsea, A.-M., De La Cruz Merino, L., Kukushkina, M., Dummer, R., Hoeller, C., Gorry, C., Bastholt, L., Herceg, D., Neyns, B., Vieira, R., Arenberger, P., Bylaite-Bucinskiene, M., Babovic, N., Banjin, M., Putnik, K., Todorovic, V., Kirov, K., Ocvirk, J., Zhukavets, A., Ymeri, A., Stojkovski, I., Garbe, C.

“…According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma…”
Get full text

Socioeconomic and migration status as predictors of emergency caesarean section: a birth cohort study by Miani, C, Ludwig, A, Breckenkamp, J, Sauzet, O, Doyle, I-M, Hoeller-Holtrichter, C, Spallek, J, Razum, O

“…Women with a migration background are reportedly at a higher risk of emergency caesarean section. There is evidence that this is due in part to suboptimal…”
Get full text

The evolving field of Dermato‐oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force by Garbe, C., Peris, K., Soura, E., Forsea, A.M., Hauschild, A., Arenbergerova, M., Bylaite, M., Marmol, V., Bataille, V., Samimi, M., Gandini, S., Saiag, P., Eigentler, T.K., Lallas, A., Zalaudek, I., Lebbe, C., Grob, J.‐J., Hoeller, C., Robert, C., Dréno, B., Arenberger, P., Kandolf‐Sekulovic, L., Kaufmann, R., Malvehy, J., Puig, S., Leiter, U., Ribero, S., Papadavid, E., Quaglino, P., Bagot, M., John, S.M., Richard, M.‐A., Trakatelli, M., Salavastru, C., Borradori, L., Marinovic, B., Enk, A., Pincelli, C., Ioannides, D., Paul, C., Stratigos, A.J.

“…Background The incidence of skin cancers has been increasing steadily over the last decades. Although there have been significant breakthroughs in the…”
Get full text

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments by Kandolf Sekulovic, L, Peris, K, Hauschild, A, Stratigos, A, Grob, J.-J, Nathan, P, Dummer, R, Forsea, A.-M, Hoeller, C, Gogas, H, Demidov, L, Lebbe, C, Blank, C, Olah, J, Bastholt, L, Herceg, D, Neyns, B, Vieira, R, Hansson, J, Rutkowski, P, Krajsova, I, Bylaite-Bucinskiene, M, Zalaudek, I, Maric-Brozic, J, Babovic, N, Banjin, M, Putnik, K, Weinlich, G, Todorovic, V, Kirov, K, Ocvirk, J, Zhukavets, A, Kukushkina, M, De La Cruz Merino, L, Ymeri, A, Risteski, M, Garbe, C

“…Abstract Background Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among…”
Get full text

Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients by Richtig, G., Hoeller, C., Kashofer, K., Aigelsreiter, A., Heinemann, A., Kwong, L.N., Pichler, M., Richtig, E.

“…Summary BRAF gene mutations can be found in approximately 50% of melanomas, but the most common BRAF mutation leads to substitution at residue 600 of the…”
Get full text

Beyond the BRAF V 600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients by Richtig, G, Hoeller, C, Kashofer, K, Aigelsreiter, A, Heinemann, A, Kwong, L N, Pichler, M, Richtig, E

“…BRAF gene mutations can be found in approximately 50% of melanomas, but the most common BRAF mutation leads to substitution at residue 600 of the protein, from…”
Get full text

Chemosensitisation of malignant melanoma by BCL2 antisense therapy by Jansen, B, Wacheck, V, Heere-Ress, E, Schlagbauer-Wadl, H, Hoeller, C, Lucas, T, Hoermann, M, Hollenstein, U, Wolff, K, Pehamberger, H

“…Chemoresistance of malignant melanoma has been linked to expression of the proto-oncogene BCL2. Antisense oligonucleotides (ASO) targeted against BCL2 mRNA…”
Get full text

Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries by Kandolf‐Sekulovic, L., Peris, K., Stratigos, A., Hauschild, A., Forsea, A.‐M., Lebbe, C., Lallas, A., Grob, J.‐J., Harwood, C., Gogas, H., Rutkowski, P., Olah, J., Kelleners‐Smeets, N.W.J., Paoli, J., Dummer, R., Moreno‐Ramirez, D., Bastholt, L., Putnik, K., Karls, R., Hoeller, C., Vandersleyen, V., Vieira, R., Arenberger, P., Bylaite‐Buckinskiene, M., Ocvirk, J., Situm, M., Weinlich, G., Banjin, M., Todorovic, V., Ymeri, A., Zhukavets, A., Garbe, C.

“…Background and objectives The incidence of melanoma is increasing. This places significant burden on societies to provide efficient cancer care. The European…”
Get full text

Detection and differentiation of Vibrio spp. in seafood and fish samples with cultural and molecular methods by Messelhäusser, U., Colditz, J., Thärigen, D., Kleih, W., Höller, C., Busch, U.

“…Vibrio spp. as natural inhabitants of sea- and brackwater of both tropical and temperate regions of the world are commonly found in different kinds of seafood…”
Get full text

Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies by Butler, M, Hamid, O, Ribas, A, Hodi, F.S, Walpole, E, Dauad, A, Arance, A, Brown, E, Hoeller, C, Mortier, L, Schachter, J, Long, J, Ebbinghaus, S, Ibrahim, N, Robert, C

Get full text

EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL) by Ascierto, P, Bastholt, L, Mohr, P, Hoeller, C, Robert, C, Larkin, J, Dummer, R, Ekbom, A, Chiarion-Sileni, V, Dutriaux, C, Mortier, L, Neyns, B, Nyakas, M, Garbe, C, Baurain, J.F, Kruse, V, Svane, I.M, Alfaya, L, Ciria, C, Blank, C

Get full text

Prevalence of emetic Bacillus cereus in different ice creams in Bavaria by Messelhäusser, U, Kämpf, P, Fricker, M, Ehling-Schulz, M, Zucker, R, Wagner, B, Busch, U, Höller, C

“…In this study, 809 samples of ice cream from different sources were investigated by using cultural methods for the presence of presumptive Bacillus cereus…”
Get more information

Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma- a single centre experience by Schicher, N., Edelhauser, G., Harmankaya, K., Schindler, K., Gleiss, A., Pehamberger, H., Hoeller, C.

“…Background  Uveal melanoma is the most common intraocular neoplasm with a high tendency to metastasize predominantly to the liver. Prognostic parameters for…”
Get full text

Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis by Roka, F, Kittler, H, Cauzig, P, Hoeller, C, Hinterhuber, G, Wolff, K, Pehamberger, H, Diem, E

“…Sentinel lymph node biopsy (SLNB) has become a widely accepted standard procedure in the staging of patients with cutaneous melanoma and absence of clinical…”
Get full text